Which class of antidepressants does not appear to cause increased risk to the fetus?

Selective serotonin reuptake inhibitors (SSRIs) are often considered to have a relatively favorable safety profile when it comes to use during pregnancy, especially compared to other classes of antidepressants. Data suggest that while there is some risk associated with SSRIs, particularly in late pregnancy regarding potential complications such as neonatal withdrawal syndrome or persistent pulmonary hypertension, overall, they are not linked to significant teratogenic effects.

Research has shown that SSRIs do not seem to increase the risk of major malformations in the fetus when taken during the first trimester. This makes SSRIs a more preferred option among healthcare providers when considering antidepressant treatment for pregnant individuals. The careful evaluation of the risks versus benefits allows healthcare professionals to weigh the established safety of SSRIs against the potential consequences of untreated depression during pregnancy, which can adversely affect both the mother and developing fetus.

In contrast, tricyclic antidepressants, monoamine oxidase inhibitors, and selective norepinephrine reuptake inhibitors have more concerns regarding their safety profiles during pregnancy. These classes may have more substantial risks of adverse effects on fetal development or neonatal health, making SSRIs a standard choice in the discussion of antidepressant use during pregnancy.